COVID-19 alert: Read about changed restrictions for businesses in Greater Brisbane from 6pm, Monday 11 January.
Type-1 regulatory T (TR1) cell therapeutic
QIMR Berghofer's researchers have discovered a novel method of identifying, extracting and generating large numbers of Type-1 regulatory T (TR1) cells capable of maintaining immune tolerance or limiting overt inflammation.
Unique selling point/competitive advantage
QIMR Berghofer has identified a critical regulator required for cellular and transcriptional control of TR1 cell development. Modulation of this critical regulator allows the generation of large numbers of TR1 cells to establish tolerance in diseases characterised by aberrant immunity and immunopathology.
Potential target indications for this technology include transplantation rejection/graft versus host disease (GVHD) and autoimmunity, including systemic lupus erythematosus and rheumatoid arthritis.
Investment or collaboration opportunities
QIMR Berghofer is exploring both licensing and investment opportunities for this technology.
Intellectual property rights
QIMR Berghofer has filed a patent application that is currently under Patent Cooperation Treaty (PCT) for methods of identifying immunosuppressive TR1 regulatory T cells, including:
- methods of diagnosing the presence of immune tolerance
- methods of producing immunosuppressive regulatory T cells
- methods of eliciting immune tolerance in a subject.
Dr Robert McLachlan
Head of Business Development
Phone: +61 407 371 096
Visit QIMR Berghofer for more information.
- Last reviewed: 17 Jul 2019
- Last updated: 29 May 2018